<DOC>
	<DOCNO>NCT00241501</DOCNO>
	<brief_summary>This study phase III , multi-centre , randomize , double-blind study ass safety tolerability daily treatment esomeprazole 20 40 mg pediatric adolescent patient 12 17 year age , inclusive , clinically diagnose GERD . The treatment period 8 week .</brief_summary>
	<brief_title>Safety Daily Dose Esomeprazole GERD Pediatric Adolescent Patients</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Provision sign write informed consent patient 's parent/guardian , assent patient prior conduct studyrelated procedure . Patients must male female age 12 17 year , inclusive . Patients must clinical diagnosis GERD make investigator base follow factor : history , physical examination , review system , laboratory test result , information diagnostic testing . Patients use PPI within 14 day prior randomization , include overthecounter PrilosecÂ® . Patients used prescription overthecounter treatment symptom gastroesophageal reflux disease ( GERD ) , Histamine 2 Receptor Antagonists ( H2RA ) prokinetics , within 3 day prior randomization . Antacids may use , except contain bismuth . Patients know hypersensitivity , allergy , intolerance component esomeprazole omeprazole .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>